These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Kendziorra K; Wolf H; Meyer PM; Barthel H; Hesse S; Becker GA; Luthardt J; Schildan A; Patt M; Sorger D; Seese A; Gertz HJ; Sabri O Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):515-25. PubMed ID: 21069319 [TBL] [Abstract][Full Text] [Related]
4. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Schmaljohann J; Gündisch D; Minnerop M; Bucerius J; Joe A; Reinhardt M; Guhlke S; Biersack HJ; Wüllner U Nucl Med Biol; 2006 Apr; 33(3):305-9. PubMed ID: 16631078 [TBL] [Abstract][Full Text] [Related]
6. The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380. Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Ellis KA; Tochon-Danguy HJ; Chan JG; O'keefe GJ; Bradley J; Savage G; Rowe CC Synapse; 2009 Sep; 63(9):752-63. PubMed ID: 19484724 [TBL] [Abstract][Full Text] [Related]
7. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease. Meyer PM; Tiepolt S; Barthel H; Hesse S; Sabri O Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):376-86. PubMed ID: 25387119 [TBL] [Abstract][Full Text] [Related]
8. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine. Sabri O; Becker GA; Meyer PM; Hesse S; Wilke S; Graef S; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Habermann B; Neuhaus P; Fischer S; Tiepolt S; Deuther-Conrad W; Barthel H; Schönknecht P; Brust P Neuroimage; 2015 Sep; 118():199-208. PubMed ID: 26037057 [TBL] [Abstract][Full Text] [Related]
9. Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease. Lorenz R; Samnick S; Dillmann U; Schiller M; Ong MF; Faßbender K; Buck A; Spiegel J Acta Neurol Scand; 2014 Sep; 130(3):164-71. PubMed ID: 24762290 [TBL] [Abstract][Full Text] [Related]
10. Acetylcholine receptors in dementia and mild cognitive impairment. Sabri O; Kendziorra K; Wolf H; Gertz HJ; Brust P Eur J Nucl Med Mol Imaging; 2008 Mar; 35 Suppl 1():S30-45. PubMed ID: 18228017 [TBL] [Abstract][Full Text] [Related]
11. PET imaging of high-affinity α4β2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics. Wong DF; Kuwabara H; Kim J; Brasic JR; Chamroonrat W; Gao Y; Valentine H; Willis W; Mathur A; McCaul ME; Wand G; Gean EG; Dannals RF; Horti AG J Nucl Med; 2013 Aug; 54(8):1308-14. PubMed ID: 23801676 [TBL] [Abstract][Full Text] [Related]
12. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Pimlott SL; Piggott M; Owens J; Greally E; Court JA; Jaros E; Perry RH; Perry EK; Wyper D Neuropsychopharmacology; 2004 Jan; 29(1):108-16. PubMed ID: 12955099 [TBL] [Abstract][Full Text] [Related]
13. Coughlin JM; Slania S; Du Y; Rosenthal HB; Lesniak WG; Minn I; Smith GS; Dannals RF; Kuwabara H; Wong DF; Wang Y; Horti AG; Pomper MG J Nucl Med; 2018 Oct; 59(10):1603-1608. PubMed ID: 29496987 [TBL] [Abstract][Full Text] [Related]
14. PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics. Kuwabara H; Wong DF; Gao Y; Valentine H; Holt DP; Ravert HT; Dannals RF; Horti AG J Nucl Med; 2012 Jan; 53(1):121-9. PubMed ID: 22173841 [TBL] [Abstract][Full Text] [Related]
15. Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. Dubroff JG; Doot RK; Falcone M; Schnoll RA; Ray R; Tyndale RF; Brody AL; Hou C; Schmitz A; Lerman C J Nucl Med; 2015 Nov; 56(11):1724-9. PubMed ID: 26272810 [TBL] [Abstract][Full Text] [Related]
16. 5-HT1B receptor imaging and cognition: a positron emission tomography study in control subjects and Parkinson's disease patients. Varrone A; Svenningsson P; Marklund P; Fatouros-Bergman H; Forsberg A; Halldin C; Nilsson LG; Farde L Synapse; 2015 Jul; 69(7):365-74. PubMed ID: 25914348 [TBL] [Abstract][Full Text] [Related]
17. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Picard F; Bruel D; Servent D; Saba W; Fruchart-Gaillard C; Schöllhorn-Peyronneau MA; Roumenov D; Brodtkorb E; Zuberi S; Gambardella A; Steinborn B; Hufnagel A; Valette H; Bottlaender M Brain; 2006 Aug; 129(Pt 8):2047-60. PubMed ID: 16815873 [TBL] [Abstract][Full Text] [Related]
18. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. Mitsis EM; Reech KM; Bois F; Tamagnan GD; Macavoy MG; Seibyl JP; Staley JK; van Dyck CH J Nucl Med; 2009 Sep; 50(9):1455-63. PubMed ID: 19690024 [TBL] [Abstract][Full Text] [Related]
19. Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Pichika R; Easwaramoorthy B; Collins D; Christian BT; Shi B; Narayanan TK; Potkin SG; Mukherjee J Nucl Med Biol; 2006 Apr; 33(3):295-304. PubMed ID: 16631077 [TBL] [Abstract][Full Text] [Related]